# **Appendix: Model description**

## 1 Epidemic model description

The model structure is shown in Figure 1. Model compartments are described in Table 1, model parameters are defined in Table 2, and population sub-groups are listed in Table 3.




Figure 1: Model diagram. Some proportion  $p_M$  of presenting cases are ascertained and isolated. Quarantined persons (shown with dashed borders) exert a lesser force of infection than non-quarantined persons.

Description	General	Quarantined
Susceptible individuals	S	_
Latent period (first stage)	$E_1$	$E_1^q$
Latent period (second stage)	$E_2$	$E_2^{\overline{q}}$
Infectious period (first stage)	$I_1$	$E_2^{\overline{q}}\\I_1^q\\I_2^q$
Infectious period (second stage)	$I_2$	$I_2^{\overline{q}}$
Recovered individuals	R	$R^{\overline{q}}$
Managed cases, ascertained upon leaving $I_1$ and	M	$M^q$
less infectious than individuals in $I_2$		
Recovered individuals that were managed cases	$M_R$	$M_R^q$
Contacts of unmanaged cases	(	$CT_{ m NM}$
Contacts of managed cases, who will enter $E_1^q$ if		$CT_{ m M}$
they become infected		

Table 1: Model compartments for the general population (middle column) and for individuals who were quarantined as a result of contact tracing (right column).

	Definition
$\sigma_1$	Inverse of first latent period.
$\sigma_2$	Inverse of second latent period.
$\gamma_1$	Inverse of first infectious period.
$\gamma_2$	Inverse of second infectious period.
$\gamma_1^q$	Inverse of first infectious period for quarantined cases.
$\gamma_2^q$	Inverse of second infectious period for quarantined cases.
$\eta$	Scaling factor for hospitalisation proportion ("severe").
$\alpha_m$	Proportion of non-severe people who present ("mild").
$\alpha$	Net proportion of people who present.
$R_0$	The basic reproduction number.
$\lambda$	The net force of infection.
$\lambda_{imp}$	The force of infection from importation.
$\beta$	The force of infection exerted by one individual.
$\kappa$	The per-person contact rate (20 people per day).
$\delta$	The duration of quarantine for contacts (14 days).
$p_M$	Probability of presenting cases being effectively managed <sup>†</sup> .
$Q_{ m eff}$	The reduction in infectiousness due to quarantine <sup>†</sup> .
$M_{ m eff}$	The reduction in infectiousness due to case management $^{\dagger}$ .
ho	The proportion of contacts (of ascertained cases) that will self-quarantine <sup>†</sup> .

Table 2: Model parameters; key intervention parameters are marked with  $\dagger$ .

Age	Indigenous	Non-Indigenous	$\Pr(\operatorname{Hosp} \operatorname{Inf})$
0-9	184,560	2,966,400	0.062%
10 - 18	149,040	2,466,480	0.062%
19 - 29	151,440	3,651,120	0.775%
30 – 39	93,360	3,315,360	2.900%
40 – 49	87,360	3,154,560	5.106%
50 – 59	66,960	2,964,720	9.895%
60 – 69	38,880	2,397,120	15.493%
70 - 79	15,360	1,423,440	35.762%
80 +	5,280	868,560	65.936%

Table 3: Population groups by age and Indigenous status, showing population sizes, and the probability of requiring hospitalisation given infection. Demographic breakdown as per Australian Bureau of Statistics resident population estimates, catalogue number 3238.0.55.001, June 2016. The values of Pr(Hosp | Inf) are upper bounds; we defined the lower bounds to be half of these listed values.

$$\frac{dS}{dt} = -\frac{S}{N} \cdot \lambda \tag{1}$$

$$\frac{dE_1}{dt} = \lambda \left(\frac{S}{N} - \rho\Theta_M\right) - \sigma_1 E_1 \tag{2}$$

$$\frac{dE_2}{dt} = \sigma_1 E_1 - \sigma_2 E_2 \tag{3}$$

$$\frac{dI_1}{dt} = \sigma_2 E_2 - \gamma_1 I_1 \tag{4}$$

$$\frac{dI_2}{dt} = \gamma_1 I_1 (1 - \alpha p_M) - \gamma_2 I_2 \tag{5}$$

$$\frac{dR}{dt} = \gamma_2 I_2 \tag{6}$$

$$\frac{dM}{dt} = \gamma_1 I_1 (\alpha p_M) - \gamma_2 M \tag{6}$$

$$\frac{dM^q}{dt} = \gamma_2^q I_1^q (\alpha p_M) - \gamma_2^q M^q \tag{7}$$

$$\frac{dR_M}{dt} = \gamma_2 M \tag{8}$$

$$\alpha = \eta + \alpha_m (1 - \eta) \tag{9}$$

$$\beta = R_0 \times \left[ (\sigma_2)^{-1} + (\gamma_1)^{-1} + (\gamma_2)^{-1} \right]^{-1} \tag{10}$$

$$\lambda = \lambda_{imp} + \beta (E_2 + I_1 + I_2) + \beta \cdot (1 - Q_{\text{eff}}) (E_2^q + I_1^q + I_2^q)$$

$$+ \beta \cdot (1 - M_{\text{eff}}) \cdot M + \beta_{M|Q} \cdot M^q$$
(11)

$$\beta_{M|Q} = \beta \cdot [1 - \max(M_{\text{eff}}, Q_{\text{eff}})] \tag{12}$$

$$\frac{dCT_{\rm M}}{dt} = \kappa \cdot (\gamma_1 I_1 + \gamma_1^q I_1^q) \cdot (\alpha \cdot p_M) - \delta CT_{\rm M} - \lambda \cdot \Theta_{\rm M}$$
(13)

$$\frac{dCT_{\text{NM}}}{dt} = \kappa \cdot (\gamma_1 I_1 + \gamma_1^q I_1^q) \cdot (1 - \alpha \cdot p_M) - \delta CT_{\text{NM}} - \lambda \cdot \Theta_{\text{NM}}$$
(14)

$$\Theta_{\rm M} = \frac{S}{N} \cdot \frac{CT_{\rm M}}{CT_{\rm M} + CT_{\rm NM}} \tag{15}$$

$$\Theta_{\rm M} = \frac{S}{N} \cdot \frac{CT_{\rm M}}{CT_{\rm M} + CT_{\rm NM}}$$

$$\Theta_{\rm NM} = \frac{S}{N} \cdot \frac{CT_{\rm NM}}{CT_{\rm M} + CT_{\rm NM}}$$

$$(15)$$

### 2 Epidemic scenarios

#### 2.1 Transmission assumptions

We base our transmission assumptions on initial estimates of a doubling time of 6.4 days and  $R_0 = 2.68$  from Wuhan [1]. In the initial version of this model, we assumed that all transmission occurred following an incubation period of 5.2 days, within a two-stage infectious period of 7.68 days required to match the doubling time,  $R_0$ , and latent duration assumptions. However, as a result of increasing evidence of the importance of pre-symptomatic transmission [2, 3], we have revised the latent period to 3.2 days in order to allow 2 days of pre-symptomatic transmission. We have elected to maintain the overall duration of infection and doubling time, which is consistent with a revised  $R_0 = 2.53$ . The two-stage latent and infectious periods now have durations of 1.6 days each (latent period), and 4 and 5.68 days respectively (infectious period). The associated generation interval for this parameterisation is 6 days.

#### 2.2 ICU and hospitalisation rates

As of February 12 2020, there had been approximately 1000 severe cases of COVID19 reported outside Hubei province in China [4]. In order to establish an overall severe case-rate we first extracted the number of cases (around 11,340) outside Hubei at this time from the China CDC descriptive epidemiology publication [5], leading to an overall severe case rate of 8.8%. As severity was not reported by age, we have used other sources to establish an appropriate age pattern, in particular the recent ICNARC report on 775 ICU admissions in the UK [6]. Briefly, we extracted data on the proportion of ICU admissions by age and gender and then age and gender standardised these using UK 2018 mid-year population figures [7], under the assumption that infection rates in adults are constant by age up to age 70. These relative weightings after standardisation and averaging over gender are 0.05 in 20-29, 0.19 in 30-39, 0.33 in 40-49 and 0.64 in 50-59, compared to the reference 60-69 year group. This allowed us to compute relative likelihoods of ICU admission by age in adults up to 70. We note that male presentations were substantially over-represented in this data, as reported in other settings but that presentations in individuals > 70 were substantially less than expected, perhaps reflecting successful mitigation of transmission to these age-groups in the UK. Therefore, to establish appropriate baseline values in 60-69, 70-70 and 80+ we drew instead on the assumptions in Imperial College report 9 and then scaled values in younger adults using the proportions described above. For children, we drew on the EpiCentro report of March 26 [8], in which 0 of 553 children with data available had been admitted to ICU. Based on comparisons to notified incidence rates in those > 80, cases in those < 20 in Italy appear at least  $30 \times$  under-reported in comparison to population proportions. Scaling up by  $30 \times$  and applying the rule of 3 [9, 10], we estimate an upper bound on ICU risk as  $1/5530 \approx 0.018\%$ , which we apply conservatively as our estimate in this age group.

In order to compute hospitalisation rates by age, we extracted the age-distribution of cases outside of China from the CCDC report, and applied our ICU rates by age, scaled up by a constant factor, so as to match the overall severe case rate of 8.8% from that setting. This exercise led to our assumption that 29% of hospitalised cases will require ICU care and is approximately equal to the proportion assumed in Imperial College Report 9.

#### 2.3 Range of scenarios

We consider the following scenarios, and provide summary statistics for each scenario in Table 4:

- The mean latent period is 3.2 days, the mean infectious period is 9.68 days, and the doubling time is 6.4 days.
- So the baseline  $R_0$  is 2.53, and the mean generation time is 6 days.
- Symptom onset occurs 2 days after the onset of infectiousness, so the mean incubation period is 5.2 days.
- Case ascertainment occurs 2 days after symptom onset.
- $\sigma_1 = \sigma_2 = 1.6$  days;  $\gamma_1 = \gamma_1^q = 4.0$  days;  $\gamma_2 = \gamma_2^q = 5.68$  days.
- There is no case isolation, or case isolation reduces transmission by 80% ( $M_{\rm eff} \in \{0, 0.8\}$ ).
- All presenting cases can be isolated  $(p_M = 1)$ .
- There is no self-quarantine (e.g., due to lack of contact tracing, or electing not to promote self-quarantine), or 80% of contacts will adhere to self-quarantine ( $\rho \in \{0, 0.8\}$ ).
- Self-quarantine halves transmission ( $Q_{\text{eff}} = 0.5$ ).
- Physical distancing measures may reduce  $R_0$  by 25% (R = 1.8975) or by 33% (R = 1.6867). We assume these measures will be applied in addition to self-quarantine and case isolation.

$R^{\dagger}$	Intervention	Attack Rate	Clinical AR	Hospital AR	Peak week
2.53	Unmitigated	89.1%	37.9%	5.4%	18
2.53	Quarantine + Isolation	(89.1%, 89.1%) 67.5% (51.4%, 76.8%)	(25.0%, 53.4%) 28.6% (21.6%, 31.2%)	(4.0%, 7.4%) $4.0%$ $(3.2%, 5.3%)$	(18, 19) $30$ $(25, 40)$
1.90	Quarantine + Isolation	37.7%	15.5%	2.2%	58
1.69	Quarantine + Isolation	(1.4%, 54.4%) $11.6%$ $(0.1%, 40.8%)$	(0.9%, 16.6%) 5.0% (0.0%, 11.5%)	$ \begin{array}{c} (0.1\%,  3.2\%) \\ 0.8\% \\ (0.0\%,  2.2\%) \end{array} $	$   \begin{array}{c}     (41, 103) \\     85 \\     (52, 104)   \end{array} $

Table 4: Key epidemic characteristics for each of the scenarios described above. Median outcomes are reported, with 5th and 95th percentiles shown below in brackets.

<sup>†:</sup> the effective reproduction number in the absence of self-quarantine and case isolation.




Figure 2: A schematic of the clinical pathways model. Repeat outpatient presentations are shown as dashed arrows. As ward bed occupancy increases, ED consultation capacity decreases (grey bar) and fewer severe cases can be triaged and admitted.

#### 3 Models of care

The structure of the clinical pathways model is shown in Figure 2, and is adapted from Moss et al. [11]. Some infected individuals will require hospitalisation ("severe cases") and of the rest, some will present to outpatient settings ("mild cases"). The proportion of mild cases that present to hospital EDs rather than to GP clinics in Australia was estimated to be 20%, based on expert consultation. It is further assumed that a fraction of the severe cases will present early in their clinical course to an outpatient setting, in advance of requiring hospitalisation. We assume that a fixed fraction of hospitalised cases require ICU admission. Parameters that govern these flows are listed in Table 5.

We assume that a proportion of infected individuals  $(\alpha_s)$  will require hospitalisation, and that this proportion varies by age. The upper bounds for each age group are listed in Table 3. A further proportion of infected individuals  $(\alpha_m)$  will present to outpatient settings but will not require hospitalisation ("mild" cases). We introduce a scaling factor  $\eta$  from which we calculate  $\alpha_s$ , and define the sampling distribution for this mild proportion as per Moss et al. [11]:

Parameter	Value
Proportion of mild cases that present to GPs	80%
Proportion of mild cases that present to EDs	20%
Proportion of mild GP cases that revisit EDs	10%
Proportion of mild ED cases that revisit GPs	5%
Proportion of severe cases that present early	50%
Proportion of early severe cases that present to GPs	80%
Proportion of early severe cases that present to EDs	20%
Proportion of non-early severe cases that present to EDs	100%
Proportion of admitted cases that require ICU	29.335%
Mean length of stay in ward beds	8 days
Mean length of stay in ICU beds	10  days
Ward bed availability threshold for reducing ED capacity	20%
Minimum ED consultation capacity	10%

Table 5: Parameters that characterise patient flows through the clinical pathways model.

$$\eta_{\text{pow}} \sim \mathcal{U}(\log_{10} 0.5, \log_{10} 1.0)$$
(17)

$$\eta = 10^{\eta_{\text{pow}}} \tag{18}$$

$$\alpha_m \sim \min(\alpha_m) + [\max(\alpha_m) - \min(\alpha_m)] \times \text{Beta}(\mu = 0.5, \text{Var} = 0.2)$$
 (19)

$$\min(\alpha_m) = 0.05 + 0.2 \cdot \frac{\eta - 0.01}{0.99} \tag{20}$$

$$\max(\alpha_m) = 0.15 + 0.6 \cdot \frac{\eta - 0.01}{0.99} \tag{21}$$

$$\alpha_s = \eta \cdot \Pr(\text{Hosp} \mid \text{Inf}) \tag{22}$$

$$\alpha = \alpha_s + (1 - \alpha_s) \cdot \alpha_m \tag{23}$$

The lower and upper bounds for  $\alpha_m$  are both linear functions of  $\eta$ . As the proportion of infected individuals who require hospitalisation increases, so too does the proportion of infected individuals will present to outpatient settings (but will not require hospitalisation).

National consultation and admission capacities for each health care setting were informed by public reports of Australian health care infrastructure, under the assumption that in a worst-case scenario up to 50% of total capacity in each health care setting could possibly be devoted to Covid-19 patients, and are listed in Table 6. Patients are admitted to general wards with a mean length of stay of 8 days, and are admitted to ICUs with a mean length of stay of 10 days. Therefore, it is the prevalence of cases requiring hospitalisation that determines the available ward and ICU bed capacities for new admissions. At a jurisdictional level, daily presentations are allocated in proportion to each jurisdiction's resident population. Health care capacity is determined based on the numbers of full time GPs per jurisdiction, the yearly number of ED presentations per jurisdiction, the number of overnight beds available in public hospitals by jurisdiction, and the number of ICU beds per jurisdiction, as described in the AIHW report "Hospital resource 2017–18: Australian hospital statistics" [12].

In the event that there is insufficient capacity in a healthcare setting for a person to receive a consultation or to be admitted to hospital, the following steps are applied:

1. Severe cases that cannot receive an ED consultation (or a consultation with an alternate care pathway, if present) are not observed by the healthcare system, and are reported as excess

	National	ACT	NSW	NT	QLD	SA	TAS	VIC	WA
ICU beds	1,114	22	437	11	206	94	25	238	81
Ward beds	25,756	448	8,832	276	5,099	1,915	557	$6,\!158$	$2,\!471$
ED consultations	10,935	202	3,945	172	2,071	694	222	2,456	1,173
GP consultations	202,999	2,607	66,616	1,582	43,627	14,005	3,935	51,338	19,289

Table 6: Estimated national and per-jurisdiction healthcare capacities, under the assumption that 50% of total capacity in each healthcare setting could possibly be devoted to Covid-19 patients. ED and GP capacities reflect maximum number of daily consultations.

demand in this care setting.

- 2. Mild cases that cannot receive an ED or GP consultation (or a consultation with an alternate care pathway, if present) are not observed by the healthcare system, and are reported as excess demand in this care setting.
- 3. Any severe cases that require ICU admission, but cannot be admitted due to a lack of available ICU beds, are considered for admission to a general ward and are reported as excess ICU demand.
- 4. Any severe cases that cannot be admitted to a general ward to a lack of available ward beds are observed by the healthcare system, and are reported as excess ward demand.

#### 3.1 Service substitution models

We consider two service-substitution models of care to circumvent EDs as the sole pathway for hospital admission:

Covid-19 Clinics dedicated COVID-19 clinics for triage and hospital admission; and

**Phone/Online** an alternative triage system to bypass GP/ED for hospital admission.

We assume that COVID-19 clinics are staffed by 10% of the GP and ED workforce, and that for each GP/ED consultation lost due to this decrease in staffing, two clinic consultations are gained. This is due to the assumption that while only 50% of GP and ED consultations may be allocated to potential COVID-19 cases, every clinic consultation is allocated to a potential COVID-19 case.

We assumed that a telephone and/or online consultation service could be staffed without materially diminishing the GP and ED work forces. The capacity of this service model was defined as 100,000 consults per day, a coarse estimate that is comparable to the consultation rate of the National Pandemic Flu Service in the United Kingdom in 2009 (around 135,000 consults per day [13]).

When one of these alternate services is provided, we assume that 25% of mild cases will use it in lieu of EDs and GPs, and that severe cases place equal demand on EDs and on these alternative services.

#### 3.2 Critical care expansion

Recall that in the base care, COVID-19 patients have access to half of all ICU beds in the healthcare system. We consider two scenarios where ICU bed capacity is expanded:

**Moderate** the number of ICU beds available to COVID-19 patients is doubled compared to the base case (i.e., 150% of total baseline ICU bed capacity); and

**Large** the number of ICU beds available to COVID-19 patients is tripled compared to the base case (i.e., 200% of total baseline ICU bed capacity); and

**Extreme** the number of ICU beds available to COVID-19 patients is increased 5-fold compared to the base case (i.e., 300% of total baseline ICU bed capacity).

#### References

- [1] J. T. Wu, K. Leung, and G. M. Leung. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. *The Lancet*, 395(10225):689–697, 2020, doi:10.1016/S0140-6736(20)30260-9.
- [2] Tapiwa Ganyani, Cecile Kremer, Dongxuan Chen, Andrea Torneri, Christel Faes, Jacco Wallinga, and Niel Hens. Estimating the generation interval for covid-19 based on symptom onset data. medRxiv, 2020, doi:10.1101/2020.03.05.20031815.
- [3] Lauren Tindale, Michelle Coombe, Jessica E Stockdale, Emma Garlock, Wing Yin Venus Lau, Manu Saraswat, Yen-Hsiang Brian Lee, Louxin Zhang, Dongxuan Chen, Jacco Wallinga, and Caroline Colijn. Transmission interval estimates suggest pre-symptomatic spread of covid-19. medRxiv, 2020, doi:10.1101/2020.03.03.20029983.
- [4] National Health Commission. National Health Commission Update on February 13, 2020. China CDC Weekly, 2020. URL http://weekly.chinacdc.cn/news/TrackingtheEpidemic.htm#NHCFeb13.
- [5] The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. Vital surveillances: The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) China, 2020. *China CDC Weekly*, 2(8):113–122, 2020. URL http://weekly.chinacdc.cn/en/article/id/e53946e2-c6c4-41e9-9a9b-fea8db1a8f51.
- [6] Intensive Care National Audit & Research Centre. ICNARC report on COVID-19 in critical care, 27 March 2020. Technical report, 2020. URL https://www.icnarc.org/About/Latest-News/2020/03/27/Report-On-775-Patients-Critically-III-With-Covid-19.
- [7] Office for National Statistics. Population estimates for the UK, England and Wales, Scotland and Northern Ireland: mid-2018. Technical report, 2019. URL https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/bulletins/annualmidyearpopulationestimates/mid2018.
- [8] Task force COVID-19. Epidemia COVID-19 Aggiornamento nazionale, 26 marzo 2020 ore 16:00. Technical report, Istituto Superiore di Sanità, 2020. URL https://www.epicentro.iss.it/coronavirus/bollettino/Bollettino-sorveglianza-integrata-COVID-19\_26-marzo%202020.pdf.
- [9] Ernst Eypasch, Rolf Lefering, C K Kum, and Hans Troidl. Probability of adverse events that have not yet occurred: a statistical reminder. BMJ, 311(7005):619–620, 1995. ISSN 0959-8138, doi:10.1136/bmj.311.7005.619.
- [10] John Ludbrook and Michael J. Lew. Estimating the risk of rare complications: is the "rule of three" good enough? *ANZ Journal of Surgery*, 79(7–8):565–570, 2009, doi:10.1111/j.1445-2197.2009.04994.x.

- [11] Robert Moss, James M. McCaw, Allen C. Cheng, Aeron C. Hurt, and Jodie McVernon. Reducing disease burden in an influenza pandemic by targeted delivery of neuraminidase inhibitors: mathematical models in the Australian context. *BMC Infectious Diseases*, 16(1):552, October 2016. ISSN 1471-2334, doi:10.1186/s12879-016-1866-7.
- [12] Australian Institute of Health and Welfare. Hospital resources 2017–18: Australian hospital statistics. Technical Report HSE 233, June 2019. URL https://www.aihw.gov.au/reports/hospitals/hospital-resources-2017-18-ahs/.
- [13] Paul Rutter, Oliver Mytton, Benjamin Ellis, and Liam Donaldson. Access to the NHS by telephone and Internet during an influenza pandemic: an observational study. *BMJ Open*, 4 (2):e004174, 2014, doi:10.1136/bmjopen-2013-004174.